newsfilter
← Earnings
Earnings Releases·

ImmunityBio — Q3 2026 Earnings Summary

ImmunityBio received FDA approval on October 14, 2026, to expand ANKTIVA's indication to include adults with BCG-unresponsive non-muscle invasive bladder cancer featuring high-grade papillary-only tumors. The company reported Q3 2026 net product revenue of $48.7 million, a 53% increase year-over-year, bringing the first nine months of 2026 revenue to $143.6 million, up 92%. Additionally, the primary endpoint was met in the QUILT-2.005 trial for BCG-naïve patients, with a supplemental Biologics License Application submission planned for the fourth quarter of 2026, while global approvals for ANKTIVA now total 35 jurisdictions.

Company
IMMUNITYBIO INC
Sector
Healthcare
Industry
Biotechnology